INNOCARE (09969) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

InnoCare Pharma Secures Waiver for Listing Rule Compliance
TipRanksJan 13 06:07 ET
InnoCare Pharma Unveils 2023 Share Award Scheme
TipRanksDec 31, 2024 04:40 ET
InnoCare Pharma Granted Waiver for Director Appointment
TipRanksDec 24, 2024 05:07 ET
InnoCare Pharma Limited's (HKG:9969) 6.0% Loss Last Week Hit Both Individual Investors Who Own 37% as Well as Institutions
Simply Wall StDec 18, 2024 19:54 ET
InnoCare Pharma Plans New Share Incentive Scheme
TipRanksNov 26, 2024 06:38 ET
Express News | InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of Tyk2 Inhibitor Icp-332 for the Treatment of Atopic Dermatitis in China
ReutersNov 14, 2024 19:30 ET

Comments

INNOCARE

May 20, 2024 22:57

Columns InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for CLL/SLL in China

InnoCare Pharma ( $INNOCARE (09969.HK)$； $InnoCare Pharma (688428.SH)$), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first patient has been dosed in a clinical trial of the Company's BCL2 inhibitor, ICP-248, in combination with orelabrutinib as a first-line therap...

1

INNOCARE

May 15, 2024 20:28

Columns InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

InnoCare Pharma ( $INNOCARE (09969.HK)$； $InnoCare Pharma (688428.SH)$), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.
This is a multicente...

1

INNOCARE

Apr 26, 2024 04:56

Columns InnoCare Sets up Specific Environment Management Target in its Fifth ESG Report

InnoCare Pharma ( $INNOCARE (09969.HK)$； $InnoCare Pharma (688428.SH)$), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the release of its 2023 Environmental, Social, and Corporate Governance (ESG) report. This marks the fifth year InnoCare has issued its ESG report, and the first year InnoCare has set up specific environmental management targets.
In the...

INNOCARE

Apr 17, 2024 20:35

Columns Study Results of Orelabrutinib in Patients with ITP Published by the American Journal of Hematology

$INNOCARE (09969.HK)$ $InnoCare Pharma (688428.SH)$ The American Journal of Hematology recently published the results of a phase II study of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in patients with patients with persistent or chronic primary immune thrombocytopenia (ITP), which evaluated the efficacy and safety of orelabrutinib in adult patients with persistent or chronic ITP. The jour...

1

INNOCARE

Mar 28, 2024 19:44

Columns InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

InnoCare Pharma ( $INNOCARE (09969.HK)$ $InnoCare Pharma (688428.SH)$), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare’s novel SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor, ICP-189, with ArriVent’s furmonertin...

4

09969 INNOCARE

Trade Overview

Capital Trend

News

Comments